IPHARMA obtained an approval to conduct phase I clinical trial of Avirus drug

In February, IPHARMA was authorized by the Ministry of Healthcare of the Russian Federation to conduct the Phase I clinical study of the medicinal product Avirus.

HCV-AVRS-01: Double-blind, randomized, placebo-controlled study to evaluate safety, tolerability and pharmacokinetics of ascending doses of Avirus study drug during single and following multiple oral dosing in healthy volunteers.

The goal of the trial is to assess safety, tolerability and pharmacokinetics of ascending doses of Avirus study drug during single and following multiple oral dosing in healthy volunteers.

Therapeutic area: Infectious diseases (chronic hepatitis C).

The Avirus drug is developed by CDRI JSC. It is an antiviral agent.

Теги:

Недавние посты
Архив

© 2020 IPHARMA

  • Facebook Social Icon
  • LinkedIn Social Icon
  • YouTube Social  Icon
  • Instagram Social Icon